Amarogentin, a secoiridoid glycoside, abrogates platelet activation through PLC γ 2 -PKC and MAPK pathways

Ting Lin Yen, Wan-Jung Lu, Li Ming Lien, Philip Aloysius Thomas, Tzu Yin Lee, Hou Chang Chiu, Joen Rong Sheu, Kuan Hung Lin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Amarogentin, an active principle of Gentiana lutea, possess antitumorigenic, antidiabetic, and antioxidative properties. Activation of platelets is associated with intravascular thrombosis and cardiovascular diseases. The present study examined the effects of amarogentin on platelet activation. Amarogentin treatment (1560 M) inhibited platelet aggregation induced by collagen, but not thrombin, arachidonic acid, and U46619. Amarogentin inhibited collagen-induced phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), and mitogen-activated protein kinases (MAPKs). It also inhibits in vivo thrombus formation in mice. In addition, neither the guanylate cyclase inhibitor ODQ nor the adenylate cyclase inhibitor SQ22536 affected the amarogentin-mediated inhibition of platelet aggregation, which suggests that amarogentin does not regulate the levels of cyclic AMP and cyclic GMP. In conclusion, amarogentin prevents platelet activation through the inhibition of PLCγ2-PKC cascade and MAPK pathway. Our findings suggest that amarogentin may offer therapeutic potential for preventing or treating thromboembolic disorders.

Original languageEnglish
Article number728019
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014

Fingerprint

Iridoid Glycosides
Platelet Activation
Type C Phospholipases
Platelets
Mitogen-Activated Protein Kinases
Protein Kinase C
Chemical activation
Platelet Aggregation
Thrombosis
Collagen
Gentiana
Agglomeration
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Phosphorylation
amarogentin
Guanylate Cyclase
Cyclic GMP
Hypoglycemic Agents
Adenylyl Cyclases
Arachidonic Acid

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Amarogentin, a secoiridoid glycoside, abrogates platelet activation through PLC γ 2 -PKC and MAPK pathways. / Yen, Ting Lin; Lu, Wan-Jung; Lien, Li Ming; Thomas, Philip Aloysius; Lee, Tzu Yin; Chiu, Hou Chang; Sheu, Joen Rong; Lin, Kuan Hung.

In: BioMed Research International, Vol. 2014, 728019, 2014.

Research output: Contribution to journalArticle

@article{7a3a6732fd6348eaaf67af89203f691a,
title = "Amarogentin, a secoiridoid glycoside, abrogates platelet activation through PLC γ 2 -PKC and MAPK pathways",
abstract = "Amarogentin, an active principle of Gentiana lutea, possess antitumorigenic, antidiabetic, and antioxidative properties. Activation of platelets is associated with intravascular thrombosis and cardiovascular diseases. The present study examined the effects of amarogentin on platelet activation. Amarogentin treatment (1560 M) inhibited platelet aggregation induced by collagen, but not thrombin, arachidonic acid, and U46619. Amarogentin inhibited collagen-induced phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), and mitogen-activated protein kinases (MAPKs). It also inhibits in vivo thrombus formation in mice. In addition, neither the guanylate cyclase inhibitor ODQ nor the adenylate cyclase inhibitor SQ22536 affected the amarogentin-mediated inhibition of platelet aggregation, which suggests that amarogentin does not regulate the levels of cyclic AMP and cyclic GMP. In conclusion, amarogentin prevents platelet activation through the inhibition of PLCγ2-PKC cascade and MAPK pathway. Our findings suggest that amarogentin may offer therapeutic potential for preventing or treating thromboembolic disorders.",
author = "Yen, {Ting Lin} and Wan-Jung Lu and Lien, {Li Ming} and Thomas, {Philip Aloysius} and Lee, {Tzu Yin} and Chiu, {Hou Chang} and Sheu, {Joen Rong} and Lin, {Kuan Hung}",
year = "2014",
doi = "10.1155/2014/728019",
language = "English",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Amarogentin, a secoiridoid glycoside, abrogates platelet activation through PLC γ 2 -PKC and MAPK pathways

AU - Yen, Ting Lin

AU - Lu, Wan-Jung

AU - Lien, Li Ming

AU - Thomas, Philip Aloysius

AU - Lee, Tzu Yin

AU - Chiu, Hou Chang

AU - Sheu, Joen Rong

AU - Lin, Kuan Hung

PY - 2014

Y1 - 2014

N2 - Amarogentin, an active principle of Gentiana lutea, possess antitumorigenic, antidiabetic, and antioxidative properties. Activation of platelets is associated with intravascular thrombosis and cardiovascular diseases. The present study examined the effects of amarogentin on platelet activation. Amarogentin treatment (1560 M) inhibited platelet aggregation induced by collagen, but not thrombin, arachidonic acid, and U46619. Amarogentin inhibited collagen-induced phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), and mitogen-activated protein kinases (MAPKs). It also inhibits in vivo thrombus formation in mice. In addition, neither the guanylate cyclase inhibitor ODQ nor the adenylate cyclase inhibitor SQ22536 affected the amarogentin-mediated inhibition of platelet aggregation, which suggests that amarogentin does not regulate the levels of cyclic AMP and cyclic GMP. In conclusion, amarogentin prevents platelet activation through the inhibition of PLCγ2-PKC cascade and MAPK pathway. Our findings suggest that amarogentin may offer therapeutic potential for preventing or treating thromboembolic disorders.

AB - Amarogentin, an active principle of Gentiana lutea, possess antitumorigenic, antidiabetic, and antioxidative properties. Activation of platelets is associated with intravascular thrombosis and cardiovascular diseases. The present study examined the effects of amarogentin on platelet activation. Amarogentin treatment (1560 M) inhibited platelet aggregation induced by collagen, but not thrombin, arachidonic acid, and U46619. Amarogentin inhibited collagen-induced phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), and mitogen-activated protein kinases (MAPKs). It also inhibits in vivo thrombus formation in mice. In addition, neither the guanylate cyclase inhibitor ODQ nor the adenylate cyclase inhibitor SQ22536 affected the amarogentin-mediated inhibition of platelet aggregation, which suggests that amarogentin does not regulate the levels of cyclic AMP and cyclic GMP. In conclusion, amarogentin prevents platelet activation through the inhibition of PLCγ2-PKC cascade and MAPK pathway. Our findings suggest that amarogentin may offer therapeutic potential for preventing or treating thromboembolic disorders.

UR - http://www.scopus.com/inward/record.url?scp=84901274033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901274033&partnerID=8YFLogxK

U2 - 10.1155/2014/728019

DO - 10.1155/2014/728019

M3 - Article

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 728019

ER -